HEPA Stock Chart & Stats
$0.10
>-$0.01(-10.27%)
At close: 4:00 PM EDT
$0.10
>-$0.01(-10.27%)
Day’s Range― - ―
52-Week Range$0.03 - $0.11
Previous Close$0.56
Volume4.66K
Average Volume (3M)24.29K
Market Cap
$8.57M
Enterprise Value-$2.02M
Total Cash (Recent Filing)$1.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.12
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding90,219,315
10 Day Avg. Volume18,147
30 Day Avg. Volume24,289
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)0.00
P/FCF Ratio-0.17
Enterprise Value/Market Cap-0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.71
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-472
Revenue Forecast (FY)N/A
Hepion Pharmaceuticals News
HEPA FAQ
What was Hepion Pharmaceuticals’s price range in the past 12 months?
Hepion Pharmaceuticals lowest stock price was $0.03 and its highest was $0.11 in the past 12 months.
What is Hepion Pharmaceuticals’s market cap?
Hepion Pharmaceuticals’s market cap is $8.57M.
When is Hepion Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Hepion Pharmaceuticals’s earnings last quarter?
Hepion Pharmaceuticals released its earnings results on May 15, 2018. The company reported -$16.8 earnings per share for the quarter.
Is Hepion Pharmaceuticals overvalued?
According to Wall Street analysts Hepion Pharmaceuticals’s price is currently Overvalued.
Does Hepion Pharmaceuticals pay dividends?
Hepion Pharmaceuticals does not currently pay dividends.
What is Hepion Pharmaceuticals’s EPS estimate?
Hepion Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hepion Pharmaceuticals have?
Hepion Pharmaceuticals has 90,219,315 shares outstanding.
What happened to Hepion Pharmaceuticals’s price movement after its last earnings report?
Hepion Pharmaceuticals reported an EPS of -$16.8 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hepion Pharmaceuticals?
Currently, no hedge funds are holding shares in HEPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hepion Pharmaceuticals
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Technical Analysis
Scinai Immunotherapeutics
―
Aditxt
―
CERo Therapeutics Holdings
―
Psyence Biomedical
―
CDT Equity
―
Ownership Overview
45.17% Insiders
1.04% Other Institutional Investors
53.79% Public Companies and
Individual Investors